33 results on '"Akamatsu, H."'
Search Results
2. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
3. 1279P First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study
4. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations
5. Impacts of the wintertime mesozooplankton community to downward carbon flux in the subarctic and subtropical Pacific Oceans
6. LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN
7. 1357P Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
8. 1263P Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)
9. 600TiP Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
10. 1501TiP A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)
11. Overcorrection in vertical alveolar distraction osteogenesis for dental implants
12. O3–099 - Surrogate Markers of Survival in Locally Advanced Non-Small Cell Lung Cancer: Meta-Analysis from Randomized Trials
13. 384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
14. 1271P A phase II study of high-flow nasal cannula as palliative care in advanced cancer patients
15. 155TiP Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
16. Influence of scandium and zirconium on grain stability and superplastic ductilities in ultrafine-grained Al–Mg alloys
17. Increase of Si solution rate into Al matrix by repeated irradiation of intense pulsed ion beam
18. 1291P A phase II study of nivolumab rechallenge therapy in advanced NSCLC patients who responded to prior anti-PD-1/L1 inhibitors: West Japan Oncology Group 9616L
19. LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC
20. 1236MO A single-arm phase II study of gefitinib with concurrent thoracic radiotherapy in unresectable locally-advanced non-small cell lung cancer patients with EGFR mutation (West Japan Oncology Group 6911L)
21. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
22. 421P - EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC)
23. 1536TiP - An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
24. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy
25. 22 - Comparison of PD-L1 expression between tumor tissues and circulating tumor cells in patients with lung cancer
26. 484PD A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer
27. 487P Establishment of novel multiplexed assay to detect EGFR mutations using ultra-sensitive digital PCR
28. 1566P - Concurrent Genetic Alterations in Lung Cancer: a Comprehensive Genomic Profiling in a Japanese Cohort
29. 244P - Plasma Epidermal Growth Factor Receptor Mutation Analyses in Japanese Advanced Non-Small-Cell Lung Cancer Patients Horboring Egfr Mutation By Rnase H-Dependent Pcr and Blocking Oligo Dependent Pcr Methods
30. WS4-2 - Disease Flare after Gefitinib Discontinuation
31. 1310P - Prognostic Impact of Serum Cyfra 21-1 In Advanced Lung Adenocarcinoma
32. A case report of trigeminal neuralgia caused by cerebellopontine angle epidermoid cyst diagnosed by magnetic resonance imaging
33. Inhibitory effect of prostaglandin E1 on human neutrophil function
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.